Renaissance Technologies LLC Boosts Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Renaissance Technologies LLC lifted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 99.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 624,500 shares of the company's stock after buying an additional 310,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.88% of Ventyx Biosciences worth $1,368,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC raised its position in Ventyx Biosciences by 273.1% during the third quarter. Barclays PLC now owns 80,295 shares of the company's stock worth $175,000 after acquiring an additional 58,776 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Ventyx Biosciences by 44.4% during the 4th quarter. Rhumbline Advisers now owns 132,825 shares of the company's stock worth $291,000 after purchasing an additional 40,813 shares in the last quarter. State Street Corp raised its position in shares of Ventyx Biosciences by 0.8% during the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company's stock worth $2,589,000 after purchasing an additional 9,783 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Ventyx Biosciences by 2.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company's stock valued at $2,196,000 after buying an additional 20,236 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Ventyx Biosciences by 5.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company's stock valued at $3,034,000 after buying an additional 77,350 shares in the last quarter. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Stock Up 3.8 %

Shares of NASDAQ:VTYX traded up $0.05 during trading on Thursday, reaching $1.38. The stock had a trading volume of 909,121 shares, compared to its average volume of 1,282,871. The stock has a market cap of $98.20 million, a P/E ratio of -0.58 and a beta of 0.75. The business has a fifty day moving average price of $1.25 and a 200-day moving average price of $1.85. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $5.66.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.13. As a group, equities analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.